20Sep 2024
Equitable access to levetiracetam for people with epilepsy

Equitable access to levetiracetam for people with epilepsy

Epilepsy affects over 50 million people globally, with a significant concentration in low-income and middle-income countries (LMICs). While about 70% of those with epilepsy could achieve seizure freedom through appropriate medications, access to essential treatments remains limited in many LMICs, particularly for vulnerable populations like women, older adults, and individuals living with HIV. Levetiracetam, a broad-spectrum anti-seizure medication, has been included in the 2023 WHO model lists of essential medicines, offering hope for improved care. However, this addition requires collaborative efforts across health systems to enhance access.

  • #neurology

Like

Save

Share